Demographic and disease characteristics
| Characteristic . | N = 26 . |
|---|---|
| Sex, n (%) | |
| Male | 14 (54) |
| Female | 12 (46) |
| Median age, y (range) | 59.5 (14-76) |
| Race, n (%) | |
| Caucasian | 18 (69) |
| Black or African American | 3 (12) |
| Multiracial | 1 (4) |
| Native Hawaiian or other Pacific Islander | 1 (4) |
| Unknown or unspecified | 3 (12) |
| Ethnicity, n (%) | |
| Not Hispanic or Latino | 19 (73) |
| Hispanic or Latino | 7 (27) |
| Diagnosis, (%) | |
| Acute myeloid leukemia | 8 (31) |
| Acute lymphoblastic leukemia | 5 (19) |
| Chronic myeloid leukemia | 2 (8) |
| Chronic lymphocytic leukemia | 1 (4) |
| Myelodysplasia/myeloproliferative | 3 (12) |
| Sickle cell anemia | 2 (8) |
| Multiple myeloma | 1 (4) |
| Other∗ | 4 (15) |
| Transplant type, n (%) | |
| Haploidentical | 12 (46) |
| Mismatched unrelated | 9 (35) |
| Matched unrelated with T-cell depletion | 4 (15) |
| Umbilical cord blood | 1 (4) |
| Preconditioning type, n (%) | |
| Myeloablative | 12 (46) |
| Reduced intensity/nonmyeloablative | 14 (54) |
| CMV donor (D)/recipient (R) serostatus, n (%) | |
| D−/R+ | 7 (27) |
| D+R+ | 9 (35) |
| D+/R− | 3 (12) |
| D−/R−† | 7 (27) |
| Receiving letermovir at baseline, n (%) | 16 (62) |
| GVHD prophylaxis, n (%) | |
| ATG | 4 (15) |
| PTCy | 21 (81) |
| Viremia at study day 1, n (%)‡ | |
| BKV | 8 (31) |
| HHV-6 | 5 (19) |
| EBV | 2 (8) |
| AdV | 1 (4) |
| None | 14 (54) |
| Characteristic . | N = 26 . |
|---|---|
| Sex, n (%) | |
| Male | 14 (54) |
| Female | 12 (46) |
| Median age, y (range) | 59.5 (14-76) |
| Race, n (%) | |
| Caucasian | 18 (69) |
| Black or African American | 3 (12) |
| Multiracial | 1 (4) |
| Native Hawaiian or other Pacific Islander | 1 (4) |
| Unknown or unspecified | 3 (12) |
| Ethnicity, n (%) | |
| Not Hispanic or Latino | 19 (73) |
| Hispanic or Latino | 7 (27) |
| Diagnosis, (%) | |
| Acute myeloid leukemia | 8 (31) |
| Acute lymphoblastic leukemia | 5 (19) |
| Chronic myeloid leukemia | 2 (8) |
| Chronic lymphocytic leukemia | 1 (4) |
| Myelodysplasia/myeloproliferative | 3 (12) |
| Sickle cell anemia | 2 (8) |
| Multiple myeloma | 1 (4) |
| Other∗ | 4 (15) |
| Transplant type, n (%) | |
| Haploidentical | 12 (46) |
| Mismatched unrelated | 9 (35) |
| Matched unrelated with T-cell depletion | 4 (15) |
| Umbilical cord blood | 1 (4) |
| Preconditioning type, n (%) | |
| Myeloablative | 12 (46) |
| Reduced intensity/nonmyeloablative | 14 (54) |
| CMV donor (D)/recipient (R) serostatus, n (%) | |
| D−/R+ | 7 (27) |
| D+R+ | 9 (35) |
| D+/R− | 3 (12) |
| D−/R−† | 7 (27) |
| Receiving letermovir at baseline, n (%) | 16 (62) |
| GVHD prophylaxis, n (%) | |
| ATG | 4 (15) |
| PTCy | 21 (81) |
| Viremia at study day 1, n (%)‡ | |
| BKV | 8 (31) |
| HHV-6 | 5 (19) |
| EBV | 2 (8) |
| AdV | 1 (4) |
| None | 14 (54) |
Adrenoleukodystrophy, cutaneous γ-δ T-cell lymphoma, diffuse large B-cell lymphoma, T-cell prolymphocytic leukemia.
One patient was reported as CMV D−/R− but had CMV viremia. Upon investigation by the site, the patient was previously reported as R+ but was presumed to have lost their CMV antibody positivity in a prior chimeric antigen receptor T-cell process.
Eight patients had viremia with a single virus (BKV, n = 4; HHV-6, n = 3; and EBV, n = 1), and 4 had viremia with 2 viruses (BKV + HHV-6, n = 2; AdV + BKV, n = 1; and BKV + EBV, n = 1).